Topotecan in the treatment of relapsed small cell lung cancer
Elisabeth QuoixService de Pneumologie, Hôpitaux Universitaires, Strasbourg, FranceAbstract: Small cell lung cancer (SCLC) represents about 15% to 20% of all lung cancers. Chemotherapy is the cornerstone of the treatment, cisplatin–etoposide combination being the most used...
Main Author: | Elisabeth Quoix |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-12-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/topotecan-in-the-treatment-of-relapsed-small-cell-lung-cancer-a2650 |
Similar Items
-
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
by: Riemsma Rob, et al.
Published: (2010-08-01) -
OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
by: Deyan Davidov
Published: (2010-11-01) -
Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
by: P. Blanchette, et al.
Published: (2012-01-01) -
Therapeutic options in older patients with metastatic non-small cell lung cancer
by: Elisabeth Quoix
Published: (2012-09-01) -
Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer
by: Cong XUE, et al.
Published: (2010-03-01)